Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S.

Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.